Ten-year clinical outcomes of everolimus- and biolimus-eluting coronary stents vs. everolimus-eluting bioresorbable vascular scaffolds-insights from the EVERBIO-2 trial.

Front Cardiovasc Med · 2024 · PMC11423422 · PMID 39323753

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

a trend toward significancep = 0.08so close (0.05 < p ≤ 0.1)

Regarding individual endpoints, the rate of MI within the target vessel was significantly higher in the BVS group ( n = 4, 5%) compared to the BES group (0, 0%; p = 0.04), with a trend toward significance when compared to the DES group (2, 1%; p = 0.08).

also in 2,953 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.